---
title: "Elicio Therapeutics, Inc. (ELTX.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/ELTX.US.md"
symbol: "ELTX.US"
name: "Elicio Therapeutics, Inc."
industry: "Biotechnology"
---

# Elicio Therapeutics, Inc. (ELTX.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [elicio.com](https://elicio.com) |

## Company Profile

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node–targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma vi...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -3.26 | 322/605 | - | - | - |
| PB | 39.15 | 428/605 | 92.21 | 37.48 | 14.84 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-01-27T05:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 2 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 8.55 |
| Highest Target | 18.00 |
| Lowest Target | 13.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/ELTX.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/ELTX.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/ELTX.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
